Figure 1
Figure 2
Figure 3
Comparison of tumour regression grade in patients with R0 resection
| IMRT-SIB But-Hadzic et al.16 N = 46 | 3D CRT Focas et al.32 N = 385 | IMRT-SIB But-Hadzic et al.16 N = 46 | IMRT-SIB Li et al.10 N = 58 | |||
|---|---|---|---|---|---|---|
| p | p | |||||
| TRG 4 | 12 (26%) | 40 (10%) | 0.004 | 12 (26 %) | 19 (33 %) | 0.302 |
| TRG 2–3 | 29 (63%) | 254 (66%) | 0.404 | 29 (63 %) | 20 (35 %) | 0.003 |
| TRG 0–1 | 5 (11%) | 91 (24%) | 0.031 | 5 (11 %) | 19 (32 %) | 0.007 |
Biologic effective dose (BED) comparison for standard 3-dimensional conformal radiotherapy (3D CRT) and intensity modulated radioation therapy with simultaneous boost (IMRT-SIB) as experimental fractionation
| Treatment | Pelvis TD/d/BED (Gy) | Tumour T≤3 TD/d/BED (Gy) | Tumour T4 TD/d/BED (Gy) |
|---|---|---|---|
| 3D CRT | 45 / 1.8 / 37.5 | 50.4 / 1.8 / 40.9 | 54 / 1.8 / 43.9 |
| IMRT-SIB | 41.8 / 1.9 / 35.9 | 46.2 / 2.1 / 42.1 | 48.4 / 2.2 / 45.2 |
Influence of potential prognostic factors on overall survival (OS) and disease free survival (DFS)
| Prognostic factor | OS | DFS |
|---|---|---|
| Age | ns | ns |
| Gender | ns | ns |
| WHO PS | ns | ns |
| Tumour grade | ns | ns |
| cTumour stage according the AJCC, 7th edition22 | ns | ns |
| cNodal stage according the AJCC, 7th edition22 | ns | ns |
| TRG | ns | ns |
| TRG prognostic group | ns | ns |
| pTumour staged | ns | ns |
| pNodal staged | p = 0.005 | p = 0.039 |
| pCR pathologic complete response | ||
| Adjuvant chemotherapy chemotherapy | ns | ns |
| 5-6 vs. ≤4 cycles calculated for 36 patients with indication for adjuvant chemotherapy; ns = not specific (p > 0.05). | p = 0.009 | p = 0.012 |